Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

Autor:	Maroto, P, Solsona, E, Gallardo, E, Mellado, B, Morote, J, Arranz, JA, Gomez-Veiga, F, Unda, M, Climent, MA, Alcaraz, A
Rok vydání:	2016
Předmět:	Algorithm Cabazitaxel Consensus Prognostic factors Hormone therapy Castration-resistant prostate cancer
Zdroj:	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname
ISSN:	1040-8428
Popis:	Treatment of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized in recent years. It is well known that androgen receptor is still active in most patients with disease progression and serum testosterone levels
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d5d3dab3858c6bc3059774f5c59566da https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7396 Zobrazit plný text záznamu Full Text from ScienceDirect